Exploring BCL-xL inhibition for the treatment of pediatric acute megakaryoblastic leukemia
Klinische Pädiatrie · 01.05.2024 · 236 (03) · 212
DOI: 10.1055/s-0044-1786613 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Pädiatrie, erschienen am 01.05.2024. Verfasst von L M Reitemeier und 6 weiteren Autor:innen.
Abstract (Originalsprache)
BCL-2 like proteins play an important role in promoting leukemia and in developing resistance to chemotherapeutics. Accordingly, BCL-2 inhibition is effective in the treatment of adult acute myeloid leukemia (AML). However, in acute megakaryoblastic leukemia, including myeloid leukemia in Down-Syndrome (ML-DS), BCL-xL is more important for controlling mitochondrial pathway of apoptosis. Indeed, ML-DS patient cells showed better in vitro response to BCL-xL blocker Navitoclax than to BCL-2 blocker Venetoclax. But Navitoclax alone does not improve survival in vivo. To further explore and enhance the effectivity of BCL-xL inhibition as therapeutic option, we performed CRISPR/Cas9 screens aiming to find genes promoting or interfering with leukemia proliferation when Navitoclax is applied. We screened genes differentially expressed between Navitoclax responders/ non-responders based proteomic data as well as on genes targeted by FDA approved drugs. We aim to identify potential drug targets sensitizing BCL-xL inhibition and to discover resistance mechanisms providing new avenues for exploring therapeutic options for various malignancies including pediatric acute megakaryoblastic leukemia. Publication History Article published online: 10 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Reitemeier, L. M., Agha-Mir-Salim, D., Wolf, S., Kaulich, M., Heckl, D., Bhayadia, R., & Klusmann, J. H. (2024). Exploring BCL-xL inhibition for the treatment of pediatric acute megakaryoblastic leukemia. Klinische Pädiatrie, 236(03), 212. https://doi.org/10.1055/s-0044-1786613
Vancouver
Reitemeier LM, Agha-Mir-Salim D, Wolf S, Kaulich M, Heckl D, Bhayadia R, et al. Exploring BCL-xL inhibition for the treatment of pediatric acute megakaryoblastic leukemia. Klinische Pädiatrie. 2024;236(03):212. doi:10.1055/s-0044-1786613
BibTeX
@article{Reitemeier2024,
author = {Reitemeier, L M and Agha-Mir-Salim, D and Wolf, S and Kaulich, M and Heckl, D and Bhayadia, R and Klusmann, J H},
title = {Exploring BCL-xL inhibition for the treatment of pediatric acute megakaryoblastic leukemia},
journal = {Klinische Pädiatrie},
year = {2024},
volume = {236},
number = {03},
pages = {212},
doi = {10.1055/s-0044-1786613}
}
EUVIMED